Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication of preclinical safety and efficacy study data using Cytori Cell Therapy™ for combined radiation and thermal injury. This preliminary study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

The paper, entitled Development of a Combined Radiation and Full Thickness Burn Injury Minipig Model to Study the Effects of Uncultured Adipose-Derived Regenerative Cell Therapy in Wound Healing, was published in the International Journal of Radiation Biology.

The paper reports that injection of Cytori Cell Therapy by either local or intravenous administration led to improvement of healing of full thickness burns that were compromised by concomitant exposure to sub-lethal, marrow-damaging total body irradiation. Treated wounds exhibited 3.5-fold greater re-epithelialization at two weeks post-treatment (relative to control), increase in blood vessel density by an average of 67%, and an increase in matrix (collagen) deposition of 30%. Similar results were observed when the Therapy was injected directly into the wound or by intravenous administration. Local and intravenous Therapy delivery were well tolerated and no serious side effects related to body weight, loss of appetite, infection, activity, or complete blood counts was observed over the course of the study.

“These preclinical data support the clinical rationale for the investigational use of topical or intravenous administration of Cytori Cell Therapy in burn patients,” said Dr. John Fraser, Cytori’s Chief Scientist. “We are leveraging this data in a forthcoming U.S. FDA investigational device exemption (IDE) application for the RELIEF Phase I clinical trial to assess the safety and feasibility of the intravenously administered Cytori Cell Therapy as a novel thermal burn countermeasure.”

The current healthcare system is ill-prepared for large numbers of patients requiring simultaneous treatment. Current standard of care consists of dressings, skin grafts, and skin substitutes. Despite these treatments, patients with severe burns commonly suffer from prolonged pain, aggressive scarring, skin contracture, and reduced range of motion. Autologous Cell Therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring and also can be deployed in a cost-effective manner, even in mass casualty situations.

In a mass casualty event, the Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, the Cytori Cell Therapy approach represents a novel potential medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and help improve casualty care. (Original Source)

Shares of Cytori Therapeutics closed last Friday at $1.84, down $0.07 or -3.66%. CYTX has a 1-year high of $6.11 and a 1-year low of $1.78. The stock’s 50-day moving average is $2.03 and its 200-day moving average is $2.54.

On the ratings front, Cytori has been the subject of a number of recent research reports. In a report issued on September 26, Maxim analyst Jason Kolbert reiterated a Buy rating on CYTX, with a price target of $5.00, which implies an upside of 172% from current levels. Separately, on June 27, Roth Capital’s Joseph Pantginis maintained a Buy rating on the stock and has a price target of $11.00.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Joseph Pantginis have a total average return of -15.4% and -12.0% respectively. Kolbert has a success rate of 26% and is ranked #4065 out of 4190 analysts, while Pantginis has a success rate of 33% and is ranked #4060.

Cytori Therapeutics, Inc. is a late stage cell therapy company. Its develops autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.